Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
INCY
INCYTE CORPORATION
NASDAQ
$122.19
▲ UP 0.59% (0.72)

KEY STATISTICS

Market Cap$24.62 B
52w High$132.60
52w Low$81.09
Dividend Yield—
Frequency—
P/E16.42
Volume1.46M
Shares Out.202.70M

COMPANY

LEADERSHIP

William J. Meury
CHIEF EXECUTIVE
William J. Meury

COMPENSATION 2026

Salary$1,392,499
Stock Awards$1,971,975
Incentive Plan Pay$1,026,072
All Other Comp.$295,945
Total$6,380,525

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 4, 1993
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
2,844

PRICE TARGET

Target High$155.00
Target Low$104.00
Target Median$130.00
Target Consensus$130.07

UPCOMING EARNINGS

DateOct 27, 2026
DayTuesday
Rev. Est.$1.47B
OCT
27
TUE

SPLIT RECORD

DATETYPERATIO
2000-09-01Forward2:1
1997-11-10Forward2:1

PRICE

$122.19 ▲ UP 0.59% (+$0.72)
OVERLAYS
$122$122$1239:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM122.19

About Incyte Corporation

https://www.incyte.com ↗

Incyte Corporation is a biopharmaceutical company developing proprietary therapies like Jakafi, Pemazyre, and Iclusig, with a diverse pipeline and collaborations targeting various cancers and immune disorders globally.

INDUSTRY

Biotechnology

A PRODUCT INCYTE CORPORATION IS KNOWN FOR

Opzelura (ruxolitinib) cream
Opzelura (ruxolitinib) cream

Opzelura is the first FDA-approved topical JAK inhibitor by Incyte, treating vitiligo and atopic dermatitis, driving strong sales growth and expanding dermatology market presence.

COMPETITORS

COMPETITOR
ABBV COMPARE
ARQT COMPARE
LLY COMPARE
PFE COMPARE
REGN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
970
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.03% · 5.4M
XUU.TO
0.03% · 2.2M
SPY
0.03% · 2.0M
RSP
0.23% · 1.8M
VETS
9.13% · 1.7M
VFLO
1.58% · 1.4M
FBT
3.34% · 775.7K
SCHM
0.39% · 464.9K
FMDE
0.66% · 434.1K
GSLC
0.27% · 327.6K
DFAC
0.08% · 305.1K
XDEW.DE
0.23% · 293.9K
QGRO
1.60% · 252.0K
DSTL
0.80% · 138.5K
FLQM
0.95% · 117.2K
WENU.L
4.28% · 115.0K
SM
SMRI
2.00% · 114.5K
JQUA
0.16% · 111.8K
SEIV
0.73% · 95.7K
QVAL
1.90% · 93.7K
JHMM
0.19% · 91.4K
BBH
2.41% · 89.6K
INFO
0.84% · 60.1K
XZ
XZME.F
0.08% · 58.6K
ZSP.TO
0.03% · 55.7K
AASU.SW
0.23% · 54.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
71.61%
HOLDERS
1,215
TOP 12 OF 1,215 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
30.8M sh · $3.49B
Blackrock Inc.
21.4M sh · $1.29B
Vanguard Group Inc
20.0M sh · $1.69B
Blackrock, Inc.
19.0M sh · $1.79B
Dodge & Cox
13.9M sh · $1.18B
State Street Corp
9.7M sh · $1.1B
Aqr Capital Management LLC
7.9M sh · $667.56M
Geode Capital Management, LLC
5.0M sh · $491.5M
Renaissance Technologies LLC
4.5M sh · $384.03M
Blackrock Fund Advisors
4.4M sh · $444.89M
Blackrock Institutional Trust Company, N.A.
4.4M sh · $444.73M
Lsv Asset Management
4.1M sh · $467.47M

RATINGS SNAPSHOT

Overall rating: A

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets5
Debt To Equity4
Price To Earnings2
Price To Book2
Overall Score4

TRADES BY CONGRESS

HOUSE TRADES
Rob Bresnahan
Rob Bresnahan
Sale
2025-05-15
 Robert P. Bresnahan
Robert P. Bresnahan
Sale
2025-05-15
 Ro Khanna
Ro Khanna
Sale
2024-09-09
 Daniel Goldman
Daniel Goldman
Sale (Full)
2023-03-06

INSIDER TRADES

★
OFFICER: EVP, HUMAN RESOURCES
Basi Ramitpal K
Sale · 504 shares
2026-08-25
★
OFFICER: PRESIDENT, GLOBAL HEAD OF R&D
CAGNONI PABLO J
Sale · 10.8K shares
2026-08-19
★
OFFICER: PRESIDENT, GLOBAL HEAD OF R&D
CAGNONI PABLO J
Sale · 10.8K shares
2026-08-12
★
OFFICER: PRESIDENT, GLOBAL HEAD OF R&D
CAGNONI PABLO J
Sale · 10.6K shares
2026-08-05

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 2
OUTPERFORM 2
EQUAL WEIGHT 2
NEUTRAL 2
HOLD 2
MARKET PERFORM 1
SECTOR PERFORM 1
PERFORM 1
IN LINE 1
18 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Piper Sandler OVERWEIGHT Mizuho OUTPERFORM Leerink Partners OUTPERFORM Barclays OVERWEIGHT BMO Capital MARKET PERFORM Guggenheim BUY RBC Capital SECTOR PERFORM

SECTORS PEERS

PEERPRICE
BIIB$217.60COMPARE
ILMN$208.31COMPARE
WAT$405.61COMPARE
RPRX$59.15COMPARE
DGX$236.82COMPARE
WST$354.78COMPARE
UTHR$504.74COMPARE
THC$262.89COMPARE